Explore 3 Stock Ideas & Industry Insights Download Free Report

Drugs Made In America Acquisition II Corp. Ordinary Shares

Financial Services US DMII

10.08USD
0.01(0.10%)

Last update at 2026-06-05T20:00:00Z

Day Range

10.0810.08
LowHigh

52 Week Range

9.8610.01
LowHigh

Fundamentals

  • Previous Close 10.07
  • Market Cap637.64M
  • Volume554
  • P/E Ratio66.73
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.81211M
  • Diluted EPS TTM0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Income before tax 4.19M -0.15172M
Minority interest - -
Net income 4.19M -0.15172M
Selling general administrative 0.49M -
Selling and marketing expenses - -
Gross profit - -
Reconciled depreciation - -
Ebit - -
Ebitda -1.30050M -0.15172M
Depreciation and amortization - -
Non operating income net other - -
Operating income -1.30050M -0.15172M
Other operating expenses 1.30M 0.15M
Interest expense - -
Tax provision - -
Interest income 4.93M -
Net interest income 4.93M -
Extraordinary items - -
Non recurring - -
Other items - -
Income tax expense - -
Total revenue 0.00000M -
Total operating expenses 1.30M 0.15M
Cost of revenue - -
Total other income expense net 5.49M -
Discontinued operations - -
Net income from continuing ops 4.19M -
Net income applicable to common shares - -
Preferred stock and other adjustments - -
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Total assets 504.96M 0.14M
Intangible assets - -
Earning assets - -
Other current assets 0.03M 0.04M
Total liab 17.80M 0.25M
Total stockholder equity 487.16M -0.11672M
Deferred long term liab - -
Other current liab 0.20M 0.00468M
Common stock 504.94M 0.00144M
Capital stock 504.94M 0.00144M
Retained earnings -17.77620M -0.15172M
Other liab - -
Good will - -
Other assets - -
Cash 0.00022M 0.02M
Cash and equivalents - -
Total current liabilities 0.30M 0.25M
Current deferred revenue - -
Net debt -0.00022M 0.23M
Short term debt - 0.25M
Short long term debt - 0.25M
Short long term debt total - 0.25M
Other stockholder equity - 0.03M
Property plant equipment - -
Total current assets 0.03M 0.06M
Long term investments - -
Net tangible assets - -
Short term investments - -
Net receivables - -
Long term debt - -
Inventory - -
Accounts payable 0.10M 0.00000M
Total permanent equity - -
Noncontrolling interest in consolidated entity - -
Temporary equity redeemable noncontrolling interests - -
Accumulated other comprehensive income - -
Additional paid in capital - -
Common stock total equity - -
Preferred stock total equity - -
Retained earnings total equity - -
Treasury stock - -
Accumulated amortization - -
Non currrent assets other 504.93M 0.08M
Deferred long term asset charges - -
Non current assets total 504.93M 0.08M
Capital lease obligations - -
Long term debt total - -
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Investments -500.00000M -
Change to liabilities - -
Total cashflows from investing activities -500.00000M -
Net borrowings -0.53378M -
Total cash from financing activities 501.00M 0.21M
Change to operating activities - -
Net income 4.19M -0.15172M
Change in cash -0.01681M 0.02M
Begin period cash flow 0.02M -
End period cash flow 0.00022M 0.02M
Total cash from operating activities -1.01823M -0.19430M
Issuance of capital stock 502.00M -
Depreciation - -
Other cashflows from investing activities -500.00000M -
Dividends paid - -
Change to inventory - -
Change to account receivables -0.81211M -
Sale purchase of stock - -
Other cashflows from financing activities 501.00M -
Change to netincome - -
Capital expenditures 0.00000M 0.00000M
Change receivables - -
Cash flows other operating - -
Exchange rate changes - -
Cash and cash equivalents changes - -
Change in working capital -0.60764M -0.04258M
Stock based compensation - -
Other non cash items -4.59764M -
Free cash flow -1.01823M -0.19430M

Peer Comparison

Sector: Financial Services Industry: Shell Companies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
DMII
Drugs Made In America Acquisition II Corp. Ordinary Shares
0.01 0.10% 10.08 66.73 - - 1.31
CLUS
CLUS
- -% 200.00 - - 0.09 0.92 0.72 -8.9658
SVMB
SavMobi Technology Inc.
- -% 1.20 - - 239.23 - 363.28 -319.6012
PBAJ
Petro Usa Inc
- -% 0.0005 - - - - -9042.9978
ALSAF
ALSAF
- -% 15.40 - - - 0.85

Reports Covered

Stock Research & News

Profile

Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.

Drugs Made In America Acquisition II Corp. Ordinary Shares

1 East Broward Boulevard, Fort Lauderdale, FL, United States, 33301

  • 954 870 3099

Key Executives

Name Title Year Born
Mr. Roger Bendelac Chief Executive Officer 1957

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.